0000899243-21-036637.txt : 20210920 0000899243-21-036637.hdr.sgml : 20210920 20210920183616 ACCESSION NUMBER: 0000899243-21-036637 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210917 FILED AS OF DATE: 20210920 DATE AS OF CHANGE: 20210920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kjellson Nina S CENTRAL INDEX KEY: 0001381980 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40800 FILM NUMBER: 211264375 MAIL ADDRESS: STREET 1: C/O INTERWEST PARTNERS STREET 2: 2710 SAND HILL ROAD, SUITE 200 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tyra Biosciences, Inc. CENTRAL INDEX KEY: 0001863127 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831476348 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2656 STATE STREET CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: (619) 728-4760 MAIL ADDRESS: STREET 1: 2656 STATE STREET CITY: CARLSBAD STATE: CA ZIP: 92008 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-09-17 2021-09-17 0 0001863127 Tyra Biosciences, Inc. TYRA 0001381980 Kjellson Nina S C/O TYRA BIOSCIENCES, INC. 2656 STATE STREET CARLSBAD CA 92008 1 0 0 0 Common Stock 2021-09-17 4 C 0 3936595 A 3936595 I By Canaan XI L.P. Common Stock 2021-09-17 4 C 0 473396 A 473396 I By 2020+ Co-Investment L.P. - Series 7 Series A Preferred Stock 2021-09-17 4 C 0 1333334 0.00 D Common Stock 3463201 0 I By Canaan XI L.P. Series B Preferred Stock 2021-09-17 4 C 0 182257 0.00 D Common Stock 473394 0 I By Canaan XI L.P. Series B Preferred Stock 2021-09-17 4 C 0 182258 0.00 D Common Stock 473396 0 I By 2020+ Co-Investment L.P. - Series 7 On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. This amendment is being filed in order to amend the number of shares reflected in Table I, Column 5, Row 1 relating to the conversion of Common Stock on 9/17/2021. The information reported in the original Form 4, filed with the Securities & Exchange Commission on September 17, 2021, is otherwise correct in all respects. /s/ John Healy, Attorney-in Fact 2021-09-20